Haleon
HLN | NYSE
$9.20
+$0.03 (+0.33%)
At close: Nov 16, 2026, 4:00 PM ET
$9.20
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:00 PM ET
Haleon Company Profile
Company profile explainedCompany Profile
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Brian James McNamara | Chief Executive Officer & Executive Director |
| Dawn Amanda Allen | Chief Financial Officer & Director |
| Tamara Rogers | Chief Marketing Officer |
| Adrian Charles Morris | General Counsel |
| Bjorn Timelin | Head of Strategy |
| Claire Dickson | Chief Digital & Technology Officer |
| Filippo Lanzi | President of EMEA & LatAm |
| Joanne Russell | Head of Investor Relations |
| Keith Choy | President of Asia Pacific |
| Line De Decker | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 6-K | Filing |
| Oct 29, 2026 | 6-K | Filing |
| Oct 01, 2026 | 6-K | Filing |
| Sep 24, 2026 | 6-K | Filing |
| Sep 18, 2026 | 6-K | Filing |
| Sep 01, 2026 | 6-K | Filing |
| Aug 26, 2026 | CERT | Filing |
| Aug 21, 2026 | 8-A12B | Filing |
| Aug 21, 2026 | 6-K | Filing |
| Aug 19, 2026 | 6-K | Filing |
Haleon
| Country | United Kingdom |
| IPO Date | Jul 25, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 24,535 |
| CEO | Brian James McNamara |
Contact Details
The Heights Weybridge,
SU KT13 0NY United Kingdom
Stock Details
| Ticker Symbol | HLN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001900304 |
| CUSIP Number | 405552100 |
| ISIN Number | US4055521003 |
| SIC Code | 2844 |
Recent News
- 5 days ago / seekingalpha.comBuy 18 Ideal 'Safer' November Dividend Dogs Of 10-Year Tenured 81
- 19 days ago / seekingalpha.comHaleon plc (HLN) Q3 2026 Sales/Trading Call Transcript
- 19 days ago / zacks.comASAIY or HLN: Which Is the Better Value Stock Right Now?
- 28 days ago / proactiveinvestors.comUBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon
- 29 days ago / globenewswire.comHaleon Launches ‘Haleon Health House,' a One-Day Interactive Wellness Pop-Up in Toronto
- 1 month ago / prnewswire.comOnly Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore
- 1 month ago / 247wallst.comGoldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors
- 1 month ago / proactiveinvestors.comUnilever on JP Morgan positive watch as Haleon faces caution
- 2 months ago / zacks.comLCUT vs. HLN: Which Stock Is the Better Value Option?
- 2 months ago / reuters.comAdvil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
Add to Watchlist
Select watchlists to add or remove HLN